News | September 16, 2025
Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Subscribe To Our Newsletter & Stay Updated
